Mineralys Therapeutics, Inc.

Contributing Author

Recent Articles by Mineralys Therapeutics, Inc.

Oct-21	Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 2 Explore-CKD Trial of Lorundrostat at American Society of Nephrology (ASN) Kidney Week 2025 MLYS GlobeNewswire
Sep-30	Mineralys Therapeutics Completes Enrollment in Phase 2 EXPLORE-OSA Trial of Lorundrostat in Obstructive Sleep Apnea and Hypertension MLYS GlobeNewswire
Sep-05	Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need MLYS GlobeNewswire
Sep-04	Mineralys Therapeutics Announces Closing of Upsized $287.5 Million Underwritten Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares MLYS GlobeNewswire
Sep-02	Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock MLYS GlobeNewswire
Sep-02	Mineralys Therapeutics Announces Proposed Public Offering of Common Stock MLYS GlobeNewswire
Aug-12	Mineralys Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update MLYS GlobeNewswire
Aug-04	Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on Tuesday, August 12, 2025 MLYS GlobeNewswire
Jun-30	Mineralys Therapeutics Announces Journal of the American Medical Association (JAMA) Publication of Pivotal Phase 3 Launch-HTN Trial for Lorundrostat MLYS GlobeNewswire
Jun-17	Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria MLYS GlobeNewswire
May-24	Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025) MLYS GlobeNewswire
May-20	Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection MLYS GlobeNewswire
May-12	Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update MLYS GlobeNewswire
May-07	Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference MLYS GlobeNewswire
May-05	Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025 MLYS GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.